Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit
This article was originally published in The Pink Sheet Daily
In the midst of a trial, Johnson & Johnson agrees to pay $158 million to settle a suit by the state of Texas alleging the company promoted Risperdal off-label to children. Two states previously won jury verdicts over the company’s marketing of the antipsychotic.
You may also be interested in...
In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.
Court throws out $1.2 billion award to the state of Arkansas over Risperdal promotions.
GSK filed suit against the attorney general of Louisiana seeking a court order prohibiting the state from using private counsel in litigation over Avandia marketing; the state is seeking more than $10 billion in penalties.